Latest News Releases From The Newsroom
Analysts: CRBU, SOPA, SNDX, TOST, BLFS, CMC, HVT, NWL, HLMN are a Buy
July 12th, 2023
Caribou Biosciences, Inc. (Nasdaq: CRBU), a company that operates in the field of genome editing and develops CRISPR-based technologies for various applications, was initiated with a Buy rating by Truist, accompanied by a price target of $23. . Read more
Lockheed Martin Bags $99M Contract; Nasdaq Notifies Enochian Biosciences
July 11th, 2023
Lockheed Martin Rotary and Mission Systems, a business segment of Lockheed Martin Corporation (NYSE: LMT), has been awarded a firm-fixed-price, cost-plus-fixed-fee, indefinite-delivery/indefinite-quantity contract worth up to $99 million. The cont. Read more
Breaking: Shift Technologies' Strategic Move, Delta Air Lines' Key Upcoming Date
July 11th, 2023
Shift Technologies, Inc. (Nasdaq: SFT) plans to restructure its workforce to align with its omnichannel sales strategy, aimed to enhance the customer experience, increase efficiency, and focus on core operations by eliminating investment in the deale. Read more
SEC Charges Merrill Lynch and Parent Company for Failing to File Suspicious Activity Reports
July 11th, 2023
FOR IMMEDIATE RELEASE 2023-128 Washington D.C. / CRWE PRESS RELEASE / July 11, 2023 - The Securities and Exchange Commission today announced charges against Merrill Lynch, Pierce, Fenner & Smith Incorporated and its parent. Read more
Byrna's Q2 Results Disappoint, electroCore Expects Upbeat Q2 Revenue
July 11th, 2023
Byrna Technologies Inc. (Nasdaq: BYRN) reported a second-quarter fiscal 2023 loss of $0.05 per share and revenue of $11.51 million. These figures fell short of the consensus estimate, which projected earnings per share of $0.01 on revenue of $12 mill. Read more
R100 Vector Deal Fuels 4DMT; ADC Therapeutics Tumbles On ZYNLONTA Trial Status
July 11th, 2023
Astellas Pharma Inc. and 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT)(4DMT) have entered into a license agreement, allowing the use of 4DMT's intravitreal retinotropic R100 vector for rare monogenic ophthalmic diseases. This includes one initial ge. Read more
AspyreRx's Approval Boosts Better Therapeutics; Financial Figures, Outlook Drive WD-40, E2open
July 11th, 2023
Shares of Better Therapeutics, Inc. (Nasdaq: BTTX) surged over 20% in after-hours trading as the company received authorization from the FDA for its groundbreaking prescription-only digital therapeutic, AspyreRx. This innovative treatment offers cogn. Read more
CalAmp Posts Loss, Eyes Strategic Options; PriceSmart Posts Mixed Financial Figures
July 10th, 2023
CalAmp Corp. (Nasdaq: CAMP) faced a first-quarter fiscal 2024 loss of $0.11 per share, falling short of the consensus earnings per share estimate of $0.04. Looking ahead, the company expects Q2 FY24 revenues to range between $67 million and $73 mi. Read more
Market Surges: Mobilicom and Novavax See Dramatic Upswing
July 10th, 2023
Shares of Mobilicom Limited (Nasdaq: MOB) climbed over 100% in early trade following the company's announcement of a significant commercial-scale purchase order from Teledyne-FLIR, one of its Tier-1 customers. The purchase order from Teledyne Tech. Read more
Market Turmoil: FMC Slumps on Lowered Revenue Outlook
July 10th, 2023
Shares of FMC Corporation (NYSE: FMC) plummeted over 6% following the release of an update on its second quarter and full-year 2023 outlook. The company now expects second-quarter revenue to be in the range of $1.00 billion to $1.03 billion, signific. Read more
Want To Find Some News?
News By Industries
Recent Posts
-
Earnings Countdown: Lockheed Martin, Stryker, and PACCAR Gear Up
January 26th, 2025Earnings Spotlight: SoFi Technologies, Sanmina, and Nucor Set to Report
January 26th, 2025Global Flag Football League Plans To Host Pro Flag Football Tournament in Las Vegas
January 23rd, 2025Earnings On Deck: Netflix, United Airlines, and Agilysys Gear Up
January 19th, 2025
Member Login